{"id":59705,"date":"2024-07-17T13:04:43","date_gmt":"2024-07-17T11:04:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/"},"modified":"2024-07-17T13:04:43","modified_gmt":"2024-07-17T11:04:43","slug":"meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/","title":{"rendered":"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–Meliora Therapeutics (\u201cMeliora\u201d), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter Weinand, former Chairman and CEO of Bayer Pharmaceuticals, as Meliora\u2019s Chairman of the Board, and the appointment of Jean-Jacques Bienaim\u00e9, former Chairman and CEO of BioMarin, to Meliora\u2019s Board of Directors as Independent Director.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are thrilled to have Dieter Weinand and Jean-Jacques Bienaim\u00e9 join Meliora\u2019s Board of Directors,\u201d stated David Li, Meliora co-founder and Chief Executive Officer. \u201cTheir expertise and leadership in drug development will be incredible assets to our company. I look forward to working closely with both to further Meliora\u2019s vision of being the world\u2019s leading machine learning oncology therapeutics company.\u201d<\/p>\n

\nDieter Weinand is an experienced business leader with over 30 years of experience in the pharmaceutical industry and the former CEO and Chairman of the Board of Bayer Pharmaceuticals. During a career stretching back over 30 years, he has held various responsibilities in general management, commercial, operational and strategic leadership roles, leading business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America and the United States, for companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi.<\/p>\n

\nHe has also led the development, launch, and commercialization of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology, and respiratory and inflammatory diseases. He is currently Chairman of the Board of Replimune (REPL), Umoja, and Inspirna, and Executive Chairman of the Board of Mnemo Therapeutics. He earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York.<\/p>\n

\n\u201cI am very pleased to become Chairman of the Board for Meliora, a company which has the potential to make a significant clinical difference in cancer patients\u2019 lives using its novel machine learning powered approach. I look forward to working together with David and the Meliora team to advance the company through its next stages of growth and to achieve its strategic business and pipeline objectives,\u201d\u00a0Mr. Weinand commented.<\/p>\n

\nMr. Jean-Jacques Bienaim\u00e9 has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals. He joined BioMarin in May 2005, when the company had a single marketed product and approximately $26 million in annual revenues. Under Mr. Bienaim\u00e9’s leadership, BioMarin grew significantly, from about 300 US-only employees to more than 3,400 people in almost 80 countries around the world and over $2.4 billion in sales in 2023. Biomarin received 8 drug approvals by the FDA during this time period.<\/p>\n

\nBefore joining BioMarin, Mr. Bienaim\u00e9 spent years in similar executive roles at other pharmaceutical and biotech companies and currently serves on the board of directors for Incyte, Immunome, Owkin, and Keros. Mr. Bienaim\u00e9 studied economics at the \u00c9cole de Commerce de Paris and received an M.B.A from the University of Pennsylvania.<\/p>\n

\n\u201cI am excited to join the Meliora Board of Directors as they endeavor to bring transformative oncology therapeutics to the patients most in need through their ML-powered approach,\u201d commented Mr. Bienaim\u00e9. \u201cIn my career, focusing on patients while leveraging the latest technology has been critical to success, and Meliora is highly aligned in this approach. I look forward to enhancing Meliora\u2019s ability to execute on its compelling vision.\u201d<\/p>\n

\nAbout Meliora Therapeutics<\/p>\n

\nMeliora Therapeutics is discovering and developing small molecule oncology therapies for high value cancer targets with its proprietary machine learning powered platform, AnchorOmics. Pairing the first multimodal, mechanism-of-action machine learning algorithm and a world-class team of scientists and engineers, Meliora is pioneering a novel approach to create life-changing therapies for cancer patients. San Francisco and Cambridge-based Meliora Therapeutics has raised $11 million to date and is led by leaders from the fields of AI, biotechnology, and drug discovery. For more information, please visit: www.melioratx.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nDavid Li, Chief Executive Officer
\n
Meliora Therapeutics
\n
Phone: 630-991-6684
\n
Email:\u00a0david@melioratherapeutics.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–Meliora Therapeutics (\u201cMeliora\u201d), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter Weinand, former Chairman and CEO of Bayer Pharmaceuticals, as Meliora\u2019s Chairman of the Board, and the appointment of Jean-Jacques Bienaim\u00e9, former Chairman and CEO of BioMarin, to Meliora\u2019s Board of Directors as Independent … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59705","6":"format-standard","7":"category-industry"},"yoast_head":"\nMeliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–Meliora Therapeutics (\u201cMeliora\u201d), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter Weinand, former Chairman and CEO of Bayer Pharmaceuticals, as Meliora\u2019s Chairman of the Board, and the appointment of Jean-Jacques Bienaim\u00e9, former Chairman and CEO of BioMarin, to Meliora\u2019s Board of Directors as Independent ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-17T11:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240716836603\/en\/2184127\/22\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors\",\"datePublished\":\"2024-07-17T11:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/\"},\"wordCount\":663,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240716836603\\\/en\\\/2184127\\\/22\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/\",\"name\":\"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240716836603\\\/en\\\/2184127\\\/22\\\/logo.jpg\",\"datePublished\":\"2024-07-17T11:04:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240716836603\\\/en\\\/2184127\\\/22\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240716836603\\\/en\\\/2184127\\\/22\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–Meliora Therapeutics (\u201cMeliora\u201d), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter Weinand, former Chairman and CEO of Bayer Pharmaceuticals, as Meliora\u2019s Chairman of the Board, and the appointment of Jean-Jacques Bienaim\u00e9, former Chairman and CEO of BioMarin, to Meliora\u2019s Board of Directors as Independent ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/","og_site_name":"Pharma Trend","article_published_time":"2024-07-17T11:04:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240716836603\/en\/2184127\/22\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors","datePublished":"2024-07-17T11:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/"},"wordCount":663,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240716836603\/en\/2184127\/22\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/","url":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/","name":"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240716836603\/en\/2184127\/22\/logo.jpg","datePublished":"2024-07-17T11:04:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240716836603\/en\/2184127\/22\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240716836603\/en\/2184127\/22\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/meliora-therapeutics-announces-appointment-of-biopharma-luminaries-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59705"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59705\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}